Loading...
•
Sep 30, 2021
Acacia Q3 2021 Earnings Report
Acacia Research reported a milestone quarter highlighted by the IPO of Oxford Nanopore Technologies Limited, resulting in substantial realized and unrealized gains.
Key Takeaways
Acacia Research reported a significant quarter with $101 million in realized and unrealized gains from its life sciences portfolio, driven by the Oxford Nanopore IPO. The company's pro forma book value increased to $6.31 per share. Additionally, Acacia completed its first operating company acquisition, Printronix.
Recognized $101 million in realized and unrealized gains from the life sciences portfolio.
Pro forma book value at September 30, 2021 increased to $6.31 per share.
Completed the acquisition of Printronix.
Recovered $256 million of the aggregate portfolio purchase price of $282 million from the life sciences portfolio.
Acacia
Acacia
Forward Guidance
Acacia is positioned as a corporate acquirer with the flexibility, capability and expertise to pursue multiple public and private opportunities.
Positive Outlook
- Expanded team.
- Bolstered capital base.
- Positioned as a corporate acquirer.
- Flexibility to pursue multiple opportunities.
- Healthy pipeline of potential attractive operating company investments.
Challenges Ahead
- Strategic plan implementation risks.
- Risks in identifying and completing acquisitions.
- Changes in demand for intellectual property rights.
- Legislative, regulatory, and competitive developments.
- General economic conditions, including the impact of the COVID-19 pandemic.